OSLI Retina

December 2016

Issue link: http://osliretina.healio.com/i/761988

Contents of this Issue

Navigation

Page 93 of 95

1164 Ophthalmic Surgery, Lasers & Imaging Retina | Healio.com/OSLIRetina 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-848-1000 Email: osli@healio.com Healio.com/OSLIRetina SLACK I N C O R P O R A T E D ® SLACK Incorporated Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson Operations Manager Cheryl McKeown Production Associate Ryan Davis Editorial Assistant Abigail Eastwood SALES Vice President, Sales and Marketing, Surgical Specialties Patrick Duffey Global Sales Director, Eye Care Group Scott Wright Senior Account Manager, Eye Care Group Jenna Gentile Director, Sales Administration and Support Carolyn Boerner Sales Administrator Wanda Granato Advertising Sales Administrator, Recruitment Joyce Seville Circulation Manager John Kain Reprints/Eprints Licensing Opportunities: Wright's Media 877-652-5295 DESIGN Creative Director Thomas Cavallaro The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Executive Vice President Richard N. Roash Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker The U.S. Food and Drug Administration (FDA) has cleared the PLEX Elite 9000 for advanced retina research, Carl Zeiss Meditec announced in a press release. This is the FDA's first clearance for swept-source optical coherence tomography (SS-OCT) imaging technology for posterior ocular structures, the release said. The platform, which consists of SS-OCT as well as OCT angiography, provides wide-field high-resolution imaging of the microstructures and microvasculature of the posterior segment. U.S. members of the Advanced Retina Imaging (ARI) Network, a global consor- tium of clinicians and scientists who work in retinal disease research, may be able to enroll patients more easily and facilitate faster institutional review board re- views for research approval because of the FDA clearance, according to the release. "This instrument opens up a new world of structural and microvascular clarity. By imaging deeper and in greater detail than ever before, we will further our under- standing of the retina and choroid, and greatly facilitate clinical trial investigations into different diseases," Philip J. Rosenfeld, MD, PhD, chairman of ARI Network, said in the release. There is a limited release of the PLEX Elite 9000 platform for retina research. Originally posted on Healio.com on November 18, 2016. PLEX Elite 9000 From Zeiss Receives FDA Clearance News and Notes Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2016. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ ophthalmology/journals/oslir. Subscription rates in the U.S. and possessions: Individuals: One year—print $207, electronic only: $184. Institutional: One year—$643. Residents and fellows: $104 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $56 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $93. Payment must accompany order. Subscrip- tion requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - December 2016